Abrdn Life Sciences Investors Fund HQL

$14.96 +0.10 (0.67%)

Valuation

Market cap
413,820,000
Revenue TTM
$23,523,699
Net income TTM
$22,352,248
PE ratio
—
Forward PE
—
Profit margin
—
Debt to equity
—

Trading

Volume
34,700
Avg volume
70,894
Day's range
$14.85 – $15.02
Shares out
27,351,000
Stochastic %K
28%
Beta
0.73
Analysts
Strong Buy
Price target
—

Price

Company profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies...

Show more

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Industry
Asset Management
Sector
Financial Services
Phone
215 405 5700
Address
1900 Market Street, Suite 200, Philadelphia, United States

Latest news

No headlines yet.